446-95-7

Basic information

• Product Name: GENISTEINE
• Synonyms: alpha-Isospartein;Isosparteine, alpha;L-alpha-Isospartein;11-ISOSPARTEINE;GENISTEINE;genisteine-alkaloid;[7S-(7alpha,7aalpha,14alpha,14aalpha)]-dodecahydro-7,14-methano-2H,6H-dipyrido[1,2-a:1',2'-e][1,5]diazocine;Genisteinhydrate
• CAS NO: 446-95-7
• Molecular Formula: C15H26N2
• Molecular Weight: 234.38
• EINECS: 207-177-5
• Product Categories: Alkaloids
• Mol File: 446-95-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 108-110°
• Boiling Point: 340.9°Cat760mmHg
• Flash Point: 148.3°C
• Appearance: /
• Density: 1.08g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.57
• PKA: 10.08±0.20(Predicted)
• CAS DataBase Reference: GENISTEINE(CAS DataBase Reference)
• NIST Chemistry Reference: GENISTEINE(446-95-7)
• EPA Substance Registry System: GENISTEINE(446-95-7)

Safety Data

• Hazardous Substances Data: 446-95-7(Hazardous Substances Data)

Usage

General Description

Genistein is a natural plant compound belonging to the group of chemicals called isoflavones, found primarily in soybeans and other legumes. It is known for its potential health benefits, including its anti-inflammatory, antioxidant, and anticancer properties. Genistein has been studied for its potential in inhibiting the growth of cancer cells and reducing the risk of certain hormone-related cancers. It also shows promise in supporting heart health by reducing cholesterol levels and improving blood vessel function. Additionally, genistein may have a role in promoting bone health and reducing the risk of osteoporosis. It is regularly consumed as a dietary supplement and is also used in various skincare and cosmetic products due to its potential anti-aging and skin-nourishing properties.

InChI:InChI=1/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14+,15+/m0/s1

Upstream product

• 505-18-0 2,3,4,5-tetrahydropyridine 
• 1476-39-7 1,5-diaminopentane dihydrochloride 
• 72074-77-2 d,l-lupanine 
• 64-19-7 acetic acid 
• 35611-60-0 11,12-dehydrolupanine 
• 64-17-5 ethanol 

Downstream Products

• 2130-67-8 Δ¹1-Dehydrospartein 
• 2130-67-8 11,12-dehydrosparteine 
• 90-39-1 (-)-sparteine 
• 2130-67-8 (+/-)-(14at)-1,3,4,7,9,10,11,13,14,14a-decahydro-2H,6H-7r,14c-methano-dipyrido[1,2-a;1',2'-e][1,5]diazocine 
• 489-72-5 (+/-)-(7ac,14at)-dodecahydro-7r,14c-methano-dipyrido[1,2-a;1',2'-e][1,5]diazocin-6-one 
• 489-72-5 17-oxosparteine 
• 489-72-5 17-oxosparteine 
• 1403749-11-0 N-m-bromobenzyl-α-isosparteinium bromide 
• 1403749-10-9 N-m-bromobenzyl-α-isosparteinium bromide 
• 1403749-09-6 N-o-bromobenzyl-α-isosparteinium bromide 
• 117634-60-3 17-phenyl-16,17-dehydrosparteinium hydroxide 

Relevant articles and documents

PROCESS FOR CONVERTING LUPANINE INTO SPARTEINE

The present invention relates to processes for preparing enantiopure Lupanine and Sparteine.

Synthesis of Cadaverine and its Incorporation into five Quinolizidine Alkaloids

Cadaverine dihydrochloride (13) was synthesised by the sequential introduction of two equivalents of sodium cyanide to a C3 precursor, and it was fed to Lupinus luteus and L. polyphyllus plants.Complete labelling patterns were obtained in five quinolizidine alkaloids by 13C n.m.r. spectroscopy.The 13C-13C doublets observed in the spectra of (-)-lupinine (3), (-)-sparteine (4), (+)-lupanine (5), (+)-13α-hydroxylupanine (6), and (+)-angustifoline (7) derived biosynthetically from the doubly labelled precursor (13) confirm the intact, specific incorporation of two cadaverine units into the tetracyclic quinolizidine alkaloid skeletons.The cadaverine (13) units are incorporated to about the same extent into each part of the quinolizidine alkaloids (3)-(7).Two of the 13C chemical shifts for lupanine (5) have been reassigned.The labelling pattern of the tricyclic alkaloid angustifoline (7) indicates that the allyl group originates by degradation of one ring of a tetracyclic precursor.

Separation of lupine alkaloids by paper electrophoresis. 2.

-